RxDoctor Payments Data

Jenny Mullins, DO

Family Medicine · Hazard, KYNPI 1457631780

Payments from drug & device makers

$459in general payments, 2019–2025

Across 23 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$92
  • AstraZeneca$69
  • GSK$55
  • Indivior Inc.$50
  • Covidien LP$44
  • Vanda Pharmaceuticals Inc.$34
  • plus $115 from 7 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$459 in reported general payments places this provider in the 40th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$642
Medicare patients
21
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$25,178
JardianceEmpagliflozin18$19,325
EliquisApixaban22$18,001
XareltoRivaroxaban28$15,156
JanuviaSitagliptin Phosphate19$12,782
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,312
MounjaroTirzepatide11$11,682
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$11,251
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,520
LinzessLinaclotide14$7,805
VascepaIcosapent Ethyl13$5,246
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$4,449
Albuterol Sulfate HfaAlbuterol Sulfate86$3,523
Novolog FlexpenInsulin Aspart15$3,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$55$23,56441 claims
PfizerEliquis$13$18,00122 claims
MerckJanuvia$11$12,78219 claims
Lilly USA, LLCMounjaro$14$11,68211 claims
AbbVieLinzess$92$7,80514 claims
AstraZenecaBevespi Aerosphere$69$4,76711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →